Ocugen, Inc.
OCU400
Retinitis Pigmentosa
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on OCU400 for Retinitis Pigmentosa is in focus around Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“These and other risks and uncertainties are more fully described in our annual and periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarte”